[1] Montoya JG,Rosso F. Is combination therapy indicated for invasive fungal infections?Yes and no[J].Curr Opin Infect Dis,2006,19(4):371-379.
[2] Nivoix Y,Zamfir A,Lutun P,et al,Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections[J].J Infect,2006,52(1):67-74.
[3] Kontoyiannis DP,Lewis RE.Combination chemotherapy for invasive fungal infections:what laboratory and clinical studies tell us so far[J].Drug Resist Updat,2003,6(1):257-269.
[4] Mukherjee PK,Sheehan DJ,Hitchcock CA,et al.Combination treatment of invasive fungal infections[J].Clin Microbiol Rev,2005,18(1):163-194.
[5] Chamilos G,Kontoyiannis DP.The rationale of combination antifungal therapy in severely immuncompromised patients:empiricism versus evidence-based medicine[J].Curr Opin Infect Dis,2006,19(4):380-385.
[6] Marr KA,Boeckh M,Carter RA,et al.Combination antifungal therapy for invasive aspergillosis[J].Clin Infect Dis,2004,39(6):797-802.
[7] Matsuoka S, Murata M. Cholesterol markedly reduces ion permeability induced by membrane-bound amphotericin B[J]. Biochim Biophys Acta, 2002,1564(2):429-434.
[8] Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity:a review[J]. J Chemother, 2000,12(6):463-470.
[9] Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures:animal experiments and clinical study[J]. J Infect Dis 2002,186(3):379-388.
[10] Louie A, Kaw P, Banerjee P,et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis[J].Antimicrob Agents Chemother, 2001, 45(2):485-494.
[11] Samaranayake YH, Samaranayake LP, Yeung KW. Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J].Chemotherapy, 2001, 47(4):279-291.
[12] Barchiesi F, Schimizzi AM, Caselli F,et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2000, 44(9):2435-2441.
[13] Popp AI, White MH, Quadri T,et al. Amphotericin B with and without itraconazole for invasive aspergillosis. A three-year retrospective study[J].Int J Infect Dis, 1999, 3(3):157-160.
[14] Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species[J].MedMycol, 2001, 39(1):91-95.
[15] Rodero L, Cordoba S, Cahn, P,et al. In vitro susceptibility studies of Cryptococcus Neoformans isolated from patients with no clinical response to amphotericin B therapy[J].J Antimicrob Chemother,2000, 45(2):239-242.
[16] Perfect JR, Dismukes WE, Dromer F,et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010,50(3):291-322.
[17] Sevtap Arikan, Mario Lozano-Chiu,Victor Paetznick, et al.In vitro synergy of caspofungin and amphotericin B Against Aspergillus and Fusarium spp[J].Antimicrob Agents Chemother,2002, 46(1):245-247.
[18] Jon AO, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin[J]. Antimicrob Agents Chemother,2005, 49 (12):4895-4902.
[19] Francesco B,Elisabetta S,Serena T, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemoth, 2007, 51(3):941-945.
[20] Ogita A, Hirooka K, Yamamoto Y, et al. Synergistic fungicidal activity of Cu2+ and allicin, an allyl sulfur compound from garlic, and its relation to the role of alkyl hydroperoxide reductase 1 as a cell surface defense in Saccharomyces cerevisiae[J]. Toxicology,2005,215(3):205-13.
[21] Xu Y, Wang Y, Yan L, et al. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans:endogenous ROS augmentation[J]. J Proteome Res,2009,8(11):5296-304.
[22] An M, Shen H, Cao Y, et al.Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans[J]. Int J Antimicrob Agents. 2009; 33(3):258-63.
[23] Cao YY,Dai BD, Wang Y, et al.In vitro activity of baicalein against Candida albicans biofilms[J]. Int J Antimicrob Agents, 2008,32:73-77.
[24] Huang S, Cao YY, Dai BD, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.Biol Pharm Bull, 2011,31:2234-2236.
[25] Fu ZJ, Lu H,Zhu ZY, et al.Combination of baicalein and amphotericin B accelerates Candida albicans apoptosis[J].Biol Pharm Bull,2011,34(2):214-218.
[26] Phillips AJ, Sudbery I, Ramsdale M.Apoptosis induced by environmental stresses and amphotericin B in Candida albicans[J]. Proc Natl Acad Sci,2003,100:14327-14332.
[27] Phillips AJ, Crowe JD, Ramsdale M.Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans[J].Proc Natl Acad Sci,2006,103:726-731.
[28] Cao YY,HuangS, Dai BD, et al.Candida albicans cells lacking CaMCA1-encoded metacaspase show resistance to oxidative stress-induced death and change in energy metabolism[J].Fungal Genet Biol,2009,46:183-189.
[29] Clancy CJ, Wingard JR, Hong-Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients:review of the literature and demonstration of invitro synergy between antifungal agents[J].Med Mycol, 2000, 38(2):169-175.
[30] Ellis M, Watson R, McNabb A,et al. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery[J].J Med Microbiol,2002, 51(1):70-75.